• GStreamer is a library for constructing graphs of media-handling components.
• Cairo is a 2D graphics library with support for multiple output devices.
• EGL is an interface between Khronos rendering APIs (such as OpenGL, OpenGL ES) and the underlying native platform windowing system.
• GLib is a general-purpose utility library, which provides many useful data types, macros, type conversions, string utilities, file utilities, a mainloop abstraction, and so on.
• OpenGLES is a royalty-free, cross-platform API for full-function 2D and 3D graphics on embedded systems – including consoles, phones, appliances and vehicles.
• Wayland is intended as a simpler replacement for X, easier to develop and maintain.
• LibPCAP is a system-independent interface for user-level packet capture.
• OpenCV (Open Source Computer Vision) is a library of programming functions mainly aimed at real-time computer vision.
• NLopt is a free/open-source library for NonLinear OPTimization, providing a common interface for a number of different free optimization routines available online as well as original implementations of various other algorithms.
• GLM (OpenGL Mathematics) is a header only C++ mathematics library for graphics software based on the OpenGL Shading Language (GLSL) specifications.
• ZLib is a software library used for data compression.
• LibSPNAV is a library to access 3D-input-devices.

Skip to content

1 day ago In a year in which the nation’s economy was nearly ground to a halt by a nasty virus, Bowling Green and Warren County saw little evidence that the coronavirus pandemic was making the local. Applicant Processing Services. Applicant Processing Services © 2018 Copyright Gemalto, Inc. All rights reserved.

Opportunity for Impact

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.
Millions of people around the world are living with a genetically defined disease. Mutations can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases. For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.

Advancing Best-in-Class Precision Therapies

At Cogent, we start with the end in mind – with the goal of delivering meaningful therapies that improve human health. We focus on diseases where the cause is well understood and is directly linked to a genetic mutation, providing a path forward to develop novel precision therapies. Our lead therapeutic (CGT9486) is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.

Our People,
Our Promise.

Cogent is driven by the patients we serve and committed to the opportunity to deliver novel precision therapies to patients with unmet medical needs. We are a Company of people who are passionate and dedicated to turning the promises of our therapies into reality in order to transform the lives of patients.

Total gross proceeds from the offering to Cogent are approximately $115.0 million CAMBRIDGE, Mass. , Dec. 4, 2020 /PRNewswire/…

read more

CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…

read more

CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice…

Cogent Driver For Ayushman Bharat

read more

CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and…

read more

CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Andrew Robbins appointed President, CEO and Director Final results from PLX9486 + sunitinib Phase 1/2 study in GIST…

Cogent Csd 200 Driver Download

read more

CAMBRIDGE, Mass. , Nov. 5, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma…

Cogent Csd200 3m

read more